oncgnostics GmbH Release: Safe Diagnostics For Women Tested HPV-Positive
JENA, GERMANY and FRICKENHAUSEN, GERMANY--(Marketwired - Jan 20, 2016) - With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. The CE IVD mark which GynTect® received in October 2015 allows the utilization of the test in laboratories in whole Europe.
GynTect® is a molecular biology test based on so-called epigenetic biomarkers, which yields early, fast and reliable results in the area of cervical cancer diagnostics. The test was developed and is produced by oncgnostics GmbH (www.oncgnostics.com), which is a spin-off from the University women's hospital Jena, Germany, founded early in 2012.
Epigenetic biomarkers yield fast and reliable results in cancer diagnostics.
The development of cancer cells from regular tissue cells is preceded or accompanied by modifications in the DNA, especially methylations. These epigenetic changes can be reliably detected in diagnostic labs by specific molecular biology methods such as the so-called methylation-specific PCR. With GynTect® oncgnostics has developed a molecular test which allows to clarify early if a patient with an abnormal Pap smear result or an infection with high-risk human papillomavirus (HPV), causative agent of cervical cancer, develops or has a cervical disease that requires treatment. Early and reliable diagnostics constitutes the specific potential of GynTect®.
Since GynTect® yields fast and reliable results, it also allows a fast and reliable detection of those women who have a disease that requires treatment. This facilitates the risk assessment during cervical cancer screening: the possibilities for a successful early treatment are improved, while unnecessary, over-hasty surgeries can be avoided.
GynTect® is a molecular biology test based on so-called epigenetic biomarkers, which yields early, fast and reliable results in the area of cervical cancer diagnostics. The test was developed and is produced by oncgnostics GmbH (www.oncgnostics.com), which is a spin-off from the University women's hospital Jena, Germany, founded early in 2012.
Epigenetic biomarkers yield fast and reliable results in cancer diagnostics.
The development of cancer cells from regular tissue cells is preceded or accompanied by modifications in the DNA, especially methylations. These epigenetic changes can be reliably detected in diagnostic labs by specific molecular biology methods such as the so-called methylation-specific PCR. With GynTect® oncgnostics has developed a molecular test which allows to clarify early if a patient with an abnormal Pap smear result or an infection with high-risk human papillomavirus (HPV), causative agent of cervical cancer, develops or has a cervical disease that requires treatment. Early and reliable diagnostics constitutes the specific potential of GynTect®.
Since GynTect® yields fast and reliable results, it also allows a fast and reliable detection of those women who have a disease that requires treatment. This facilitates the risk assessment during cervical cancer screening: the possibilities for a successful early treatment are improved, while unnecessary, over-hasty surgeries can be avoided.